SUPNSUPERNUS PHARMACEUTICALS, INC.同业对比
SUPERNUS PHARMACEUTICALS, INC. 与SIC 2834 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUPN本股 | $1.6B#7 | — | 1.5x#3 | 2.3x#1 | 8.6%#8 | -152.2%#11 | -8.7%#4 | -3.6%#6 | -4.8%#4 | — | -9.7%#3 | — |
| PGEN | $1.9B#2 | — | 43.1x#11 | 194.1x#8 | 146.7%#3 | -98.6%#10 | -1141.1%#9 | -575.1%#12 | -91.2%#6 | — | — | — |
| GENB | $1.8B#4 | — | 3.9x#5 | — | — | — | — | 0.0%#3 | — | — | — | — |
| SLS | $1.8B#3 | — | 13.0x#9 | — | -100.0%#10 | 13.0%#5 | — | -19.5%#8 | — | — | 392.8%#1 | — |
| STOK | $1.8B#5 | — | 5.0x#6 | 9.6x#4 | 404.5%#2 | 92.3%#3 | -11.2%#5 | -2.0%#5 | — | — | — | — |
| NUVB | $1.6B#6 | — | 6.5x#7 | 26.2x#6 | 699.0%#1 | 64.0%#4 | -338.7%#7 | -80.6%#10 | -87.4%#5 | — | — | — |
| RARE | $1.6B#8 | — | — | 2.4x#2 | 20.2%#6 | -1.1%#6 | -79.5%#6 | — | — | — | -50.3%#5 | — |
| TRAX | $1.9B#1 | — | 12.9x#8 | — | — | -1.5%#7 | — | -110.0%#11 | — | — | — | — |
| KLRA | $1.6B#9 | — | 1.5x#2 | — | — | — | — | 0.0%#3 | — | — | — | — |
| ANIP | — | 15.7x#2 | — | — | 43.8%#5 | 510.5%#2 | 12.6%#2 | 13.1%#2 | 16.9%#1 | — | -23.1%#4 | — |
| INVA | $1.5B#10 | 4.9x#1 | 1.2x#1 | 3.7x#3 | 14.7%#7 | 1059.2%#1 | 39.8%#1 | 22.0%#1 | 14.7%#2 | 5#1 | 15.7%#2 | — |
| OCUL | $1.5B#11 | — | 2.9x#4 | 28.9x#7 | -18.5%#9 | -37.4%#9 | -519.8%#8 | -51.1%#9 | — | — | — | — |
| ETON | $1.5B#12 | — | 31.3x#10 | 18.2x#5 | 104.9%#4 | -20.4%#8 | -1.1%#3 | -9.9%#7 | -1.8%#3 | 4#2 | — | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议